Eduardo Dunayevich, MD | Psychiatrist.com

Article

Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive Disorder: Results of a Pilot Study

June 20, 2013

In this study, 25 overweight or obese women with major depressive disorder received up to 24 weeks of open-label treatment with a combination of 32 mg per day of...

Susan L. McElroy, Anna I. Guerdjikova, Dennis D. Kim, et al

Original Research

Case Reports of Postmarketing Adverse Event Experiences With Olanzapine Intramuscular Treatment in Patients With Agitation

February 9, 2010

Stephen R. Marder, Sebastian Sorsaburu, Eduardo Dunayevich, et al

Original Research

Longer Time to Antipsychotic Treatment Discontinuation for Any Cause Is Associated With Better Functional Outcomes for Patients With Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder

August 15, 2007

Eduardo Dunayevich, Haya Ascher-Svanum, Fangyi Zhao, et al

Original Research

Efficacy of Duloxetine for the Treatment of Generalized Anxiety Disorder: Implications for Primary Care Physicians

April 16, 2007

Hannu Koponen, Christer Allgulander, Janelle Erickson, et al

Letter to the Editor

Development of an Atherogenic Metabolic Risk Factor Profile Associated With the Use of Atypical Antipsychotics.

January 15, 2005

James L. Karagianis, Eduardo Dunayevich

Original Research

Twelve-Month Outcome in Bipolar Patients With and Without Personality Disorders

July 31, 2000

Eduardo Dunayevich, Kenji W. Sax, Susan L. McElroy, et al